The protective effect of ulinastatin combined with Xuebijing on myocardial injuries in patients with severe pneumonia

• Published in: American journal of translational research 2021-01, Vol.13 (10), p.11745-11751
• Main Authors: Wang, Sha, Dong, Yiming, Wang, Jingfeng, Leng, Lihong, Song, Xianfang, Huang, Wanyang
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 1943-8141; 1943-8141

OBJECTIVETo explore the protective effect of ulinastatin combined with Xuebijing on myocardial injuries in patients with severe pneumonia. METHODSThe clinical data of 86 patients with severe pneumonia treated in our hospital were analyzed retrospectively. According to the treatment method each patient was administered, they were divided into a control group (43 cases, routine treatment + Xuebijing) and an observation group (43 cases, routine treatment + Xuebijing + ulinastatin). All the patients were treated for 2 weeks. The clinical efficacy, the inflammatory factor levels (TNF-α, C-reactive protein (CRP), and procalcitonin (PCT)), the myocardial index levels (creatine kinase-myocardial band (CK-MB), lactic dehydrogenase (LDH), α-hydroxybutyrate dehydrogenase (α-HBDE), N-terminal pro-brain natriuretic peptide (NT-proBNP), and cardiac troponin I (cTn I)), the blood gas index levels (arterial partial pressure of oxygen (PaO2), oxygen saturation (SaO2), and oxygenation index (OI)), the coagulation functions (prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen (FIB)) and the acute physiology and chronic health evaluation (APACHE-II) scores were compared between the two groups. RESULTSAfter the treatment, the total effective rate in the observation group was higher than it was in the control group (P